{"title":"Tocilizumab","description":null,"products":[{"product_id":"actemra-162mg-0-9ml-inj","title":"ACTEMRA 162MG\/0.9ML INJ","description":"\u003ch1\u003eACTEMRA 162MG\/0.9ML INJECTION ONLINE AT BEST PRICE IN PAKISTAN\u003c\/h1\u003e\n\u003ch3\u003e\n\u003cb\u003eGENERIC: \u003c\/b\u003eTocilizumab 162mg\/0.9ml (Subcutaneous Injection)\u003c\/h3\u003e\n\u003ch3\u003e\n\u003cb\u003eMANUFACTURER:\u003c\/b\u003e Roche Pakistan Ltd\u003c\/h3\u003e\n\u003ch3\u003e\u003cb\u003eQUANTITY:\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp class=\"MsoNormal\" style=\"margin-bottom: 6.0pt;\"\u003eSingle pre-filled syringe, 0.9ml\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-size: 16.0pt; mso-bidi-font-size: 14.0pt;\"\u003eINDICATION\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"MsoNormal\" style=\"margin-bottom: 6.0pt;\"\u003eActemra 162mg Inj is a humanized anti-interleukin-6 receptor monoclonal antibody indicated for the treatment of moderate to severe active rheumatoid arthritis in adults who have had an inadequate response to disease-modifying antirheumatic drugs (DMARDs). It is also indicated for giant cell arteritis (GCA) in adults, active systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years and above, and severe or life-threatening cytokine release syndrome (CRS) induced by CAR-T cell therapy.\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-size: 16.0pt; mso-bidi-font-size: 14.0pt;\"\u003eMECHANISM OF ACTION\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"MsoNormal\" style=\"margin-bottom: 6.0pt;\"\u003eTocilizumab is a recombinant humanized IgG1 kappa monoclonal antibody that specifically binds to both soluble and membrane-bound interleukin-6 receptors (IL-6R), blocking IL-6 signaling. IL-6 is a pleiotropic pro-inflammatory cytokine produced by immune and non-immune cells that plays a central role in the pathogenesis of rheumatoid arthritis, GCA, and cytokine release syndrome by driving inflammation, autoantibody production, synovial hyperplasia, and joint destruction. By blocking the IL-6 receptor, tocilizumab prevents IL-6-mediated downstream signaling through JAK-STAT pathways, reducing the production of acute phase reactants, suppressing inflammatory cell recruitment, and halting progressive joint damage.\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-size: 16.0pt; mso-bidi-font-size: 14.0pt;\"\u003eDOSAGE AND ADMINISTRATION\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e      \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003eRheumatoid arthritis: 162mg subcutaneously every week, or every two weeks if used with DMARDs\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e      \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003eGiant cell arteritis: 162mg subcutaneously every week in combination with a tapering glucocorticoid course\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e      \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003eAdminister by subcutaneous injection in the thigh, abdomen, or upper arm, alternating sites\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e      \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003eAll dosing is under specialist supervision; screen for tuberculosis and hepatitis before initiating therapy\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-size: 16.0pt; mso-bidi-font-size: 14.0pt;\"\u003eSIDE EFFECTS\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"MsoNormal\" style=\"margin-bottom: 4.0pt;\"\u003e\u003cb\u003eCommon:\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e      \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003eNasopharyngitis and upper respiratory tract infections\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e      \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003eHypertension\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e      \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003eElevated total cholesterol, LDL, and triglycerides (monitor lipid profile)\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e      \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003eInjection site reactions: erythema, pruritus, and pain\u003c\/p\u003e\n\u003cp class=\"MsoNormal\" style=\"margin-bottom: 4.0pt;\"\u003e\u003cb\u003eLess common:\u003c\/b\u003e\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e      \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003eSerious infections including bacterial, viral, fungal, and opportunistic infections (interrupt treatment if serious infection develops)\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e      \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003eGastrointestinal perforation in patients with pre-existing diverticulitis (rare but serious)\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e      \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003eElevated liver enzymes and hepatotoxicity\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e      \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003eNeutropenia and thrombocytopenia (monitor CBC regularly)\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-size: 16.0pt; mso-bidi-font-size: 14.0pt;\"\u003eNOT RECOMMENDED IN\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e      \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003eActive, serious infections including tuberculosis (screen all patients before initiation)\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e      \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003eKnown hypersensitivity to tocilizumab\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e      \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003eNeutrophil count below 2000\/mm3, platelet count below 100,000\/mm3, or ALT\/AST above 1.5 times upper limit of normal before initiation\u003c\/p\u003e\n\u003cp class=\"MsoListParagraph\" style=\"text-indent: -.25in; mso-list: l0 level1 lfo1; margin: 0in 0in 4.0pt .5in;\"\u003e\u003c!-- [if !supportLists]--\u003e\u003cspan style=\"mso-list: Ignore;\"\u003e•\u003cspan style=\"font: 7.0pt 'Times New Roman';\"\u003e      \u003c\/span\u003e\u003c\/span\u003e\u003c!--[endif]--\u003eLive vaccines should not be given during tocilizumab therapy; update vaccinations before starting\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-size: 16.0pt; mso-bidi-font-size: 14.0pt;\"\u003eDRUG INTERACTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"MsoNormal\" style=\"margin-bottom: 6.0pt;\"\u003eTocilizumab suppresses IL-6 signaling, which can normalize CYP450 enzyme activity suppressed during inflammation. This increases metabolism of drugs that are CYP450 substrates, potentially reducing their plasma levels; drugs particularly affected include statins, cyclosporine, theophylline, warfarin, and some oral contraceptives. Monitor drug levels and adjust doses as needed when starting or stopping tocilizumab. Avoid combination with other biological DMARDs such as TNF antagonists due to increased immunosuppression and infection risk.\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-size: 16.0pt; mso-bidi-font-size: 14.0pt;\"\u003eSTORAGE INSTRUCTIONS\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"MsoNormal\" style=\"margin-bottom: 6.0pt;\"\u003eStore between 2°C and 8°C (refrigerate). Protect from light. Do not freeze or shake. Allow to reach room temperature before injection. Keep out of reach of children.\u003c\/p\u003e\n\u003ch2\u003e\u003cspan style=\"font-size: 16.0pt; mso-bidi-font-size: 14.0pt;\"\u003eWHERE TO BUY\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp class=\"MsoNormal\" style=\"margin-bottom: 6.0pt;\"\u003eYou can buy Actemra 162mg\/0.9ml injection online from Dawa Healthcare Pharmacy at dawahealthcare.biz, one of Pakistan's most trusted pharmacies for authentic, pharmacist-verified medicines. Browse our product page to check the current Actemra 162mg\/0.9ml injection price in pakistan, read detailed clinical information, and place your order from the comfort of your home. Our experienced pharmacist at branch is always available to answer your questions about Actemra 162mg\/0.9ml injection. Customers in Karachi enjoy same-day delivery on orders placed before the daily cutoff, while customers across Pakistan benefit from our nationwide courier service for safe and timely delivery to any city. You can also visit any of our Karachi branches in person or reach our dedicated WhatsApp support team for instant help with Actemra 162mg\/0.9ml injection uses, pricing, prescriptions, and order placement.\u003c\/p\u003e\n\u003cp class=\"MsoNormal\" style=\"margin-bottom: 6.0pt;\"\u003e \u003c\/p\u003e","brand":"Dawa Healthcare","offers":[{"title":"Pack","offer_id":50439550796059,"sku":"14390","price":76772.2,"currency_code":"PKR","in_stock":false},{"title":"Unit","offer_id":50439550828827,"sku":"14390","price":19193.0,"currency_code":"PKR","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0772\/8041\/1931\/files\/ACTEMRA162MG-0.9MLINJ.jpg?v=1775598830"}],"url":"https:\/\/dawahealthcare.biz\/collections\/tocilizumab.oembed","provider":"Dawa Healthcare","version":"1.0","type":"link"}